Literature DB >> 20555019

Adjuvant high-dose interferon-{alpha} for resected melanoma in a patient with HIV infection.

Nakhle S Saba1, Thomas J George, Brian C Boulmay.   

Abstract

Adjuvant interferon (IFN)-alpha remains the standard adjuvant therapy for intermediate and high-risk melanoma after definitive surgical resection. Data addressing the role and safety of adjuvant immunotherapy in HIV-infected patients with melanoma are lacking. We report on an HIV(+) patient who received IFN-alpha as adjuvant treatment for high-risk melanoma. To our knowledge, this is the first reported case of such an approach.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20555019      PMCID： PMC3228003          DOI： 10.1634/theoncologist.2009-0335

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  31 in total

Review 1.  Do sunscreens increase or decrease melanoma risk: an epidemiologic evaluation.

Authors:  M A Weinstock
Journal:  J Investig Dermatol Symp Proc       Date:  1999-09

2.  Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication.

Authors:  A Hatzakis; P Gargalianos; V Kiosses; M Lazanas; V Sypsa; C Anastassopoulou; V Vigklis; H Sambatakou; C Botsi; D Paraskevis; C Stalgis
Journal:  J Interferon Cytokine Res       Date:  2001-10       Impact factor: 2.607

3.  Melanoma incidence and mortality among US whites, 1969-1999.

Authors:  Alan C Geller; Donald R Miller; George David Annas; Marie-France Demierre; Barbara A Gilchrest; Howard K Koh
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

Review 4.  Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

Authors:  Simone Mocellin; Sandro Pasquali; Carlo R Rossi; Donato Nitti
Journal:  J Natl Cancer Inst       Date:  2010-02-23       Impact factor: 13.506

5.  A randomized trial of interferon alpha therapy for HIV type 1 infection.

Authors:  D W Haas; J Lavelle; J P Nadler; S B Greenberg; P Frame; N Mustafa; M St Clair; R McKinnis; L Dix; M Elkins; J Rooney
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

6.  Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome.

Authors:  Ousmane M Diop; Mickaël J-Y Ploquin; Lorenzo Mortara; Abdourahmane Faye; Béatrice Jacquelin; Désirée Kunkel; Pierre Lebon; Cécile Butor; Anne Hosmalin; Françoise Barré-Sinoussi; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  Increasing burden of melanoma in the United States.

Authors:  Eleni Linos; Susan M Swetter; Myles G Cockburn; Graham A Colditz; Christina A Clarke
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

8.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.

Authors:  Pragna Patel; Debra L Hanson; Patrick S Sullivan; Richard M Novak; Anne C Moorman; Tony C Tong; Scott D Holmberg; John T Brooks
Journal:  Ann Intern Med       Date:  2008-05-20       Impact factor: 25.391

Review 9.  Pros and cons of adjuvant interferon in the treatment of melanoma.

Authors:  Michael S Sabel; Vernon K Sondak
Journal:  Oncologist       Date:  2003

Review 10.  Surgery and radiotherapy in the treatment of cutaneous melanoma.

Authors:  A Testori; P Rutkowski; J Marsden; L Bastholt; V Chiarion-Sileni; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.